Spinal Cord Stimulation Devices Market Report 2025

This Spinal Cord Stimulation Devices market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The spinal cord stimulation devices market size has grown strongly in recent years. It will grow from $2.74 billion in 2024 to $2.99 billion in 2025 at a compound annual growth rate (CAGR) of 9.01%. The growth during the historic period was driven by improved clinical outcomes and higher patient satisfaction, increased awareness of pain management alternatives, expanded reimbursement support, a rise in clinical research and regulatory approvals, and the growth of pain management clinics and centers.

The spinal cord stimulation devices market size is expected to see strong growth in the next few years. It will grow to $4.18 billion in 2029 at a compound annual growth rate (CAGR) of 8.75%. In the forecast period, growth is expected to be fueled by the increasing prevalence of chronic pain conditions, rising demand for non-opioid pain management solutions, a growing geriatric population, supportive reimbursement policies, heightened adoption of wireless and rechargeable devices, and greater awareness of neuromodulation therapies among healthcare professionals and patients. Key trends anticipated include advancements in minimally invasive technologies, innovations in wireless and rechargeable devices, improvements in frequency stimulation, adoption of closed-loop feedback systems, integration of wireless connectivity, the development of advanced waveform options, and the use of personalized pain management algorithms.

The increasing prevalence of chronic pain is expected to propel the growth of the spinal cord stimulation (SCS) devices market. Chronic pain, characterized by persistent pain lasting 12 weeks or longer, often arises from conditions such as arthritis, neuropathy, or low back pain. This increase is driven by factors such as an aging population, lifestyle changes, chronic health conditions, and injuries or trauma. SCS devices help alleviate chronic pain by delivering electrical impulses to modify pain signals, offering relief for long-term conditions. For example, in November 2024, the Centers for Disease Control and Prevention (CDC) reported that in 2023, 24.3% of adults experienced chronic pain, with 8.5% reporting high-impact chronic pain, accounting for 34.9% of chronic pain cases. These trends underscore the rising demand for SCS devices in managing chronic pain effectively.

Leading companies in the spinal cord stimulation (SCS) devices market are prioritizing the development of advanced technologies, such as rechargeable SCS systems, to enhance patient care, extend device lifespan, and offer tailored pain management solutions for chronic pain sufferers. These rechargeable SCS systems are sophisticated medical devices that use electrical impulses to alleviate chronic pain by targeting the spinal cord. For example, in December 2022, Abbott Laboratories, a prominent US-based medical device manufacturer, secured FDA approval for its Eterna spinal cord stimulation system. This innovative solution is designed to revolutionize chronic pain management by combining a compact, patient-friendly design with advanced features that enhance comfort and reduce the physical burden on users. The rechargeable capability ensures the device's longevity, minimizing the need for frequent surgical replacements and boosting convenience. Moreover, the system offers precise stimulation, enabling customized pain relief tailored to each patient's unique needs. Its streamlined design supports minimally invasive implantation, promoting faster recovery times and improving overall patient outcomes.

In November 2023, Boston Scientific Corporation strengthened its chronic pain treatment portfolio by acquiring Relevant Medsystems Inc. for $850 million. This acquisition added basivertebral nerve ablation therapy, provided by Relevant Medsystems, to Boston Scientific's suite of chronic pain solutions, which includes spinal cord stimulation devices. Relevant Medsystems, known for its innovative chronic pain management technologies, enhances Boston Scientific's ability to offer comprehensive treatment options for patients suffering from persistent pain.

Major players in the spinal cord stimulation devices market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Nevro Corp., Bluewind Medical, NeuroPace Inc., Vertos Medical Inc., SPR Therapeutics Inc., Saluda Medical Pty Ltd., Stimwave Technologies Inc., Nuvectra Inc., Soterix Medical Inc., Synapse Biomedical, ONWARD Medical NV, NeuroSigma Inc., Nalu Medical Inc., Neurostim Technologies, SpineX Inc., Aleva Neurotherapeutics SA, GTX Medical BV.

North America was the largest region in the spinal cord stimulation devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in spinal cord stimulation devices report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the spinal cord stimulation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Spinal cord stimulation (SCS) devices are implantable medical devices that help manage chronic pain by delivering gentle electrical pulses to the spinal cord. These pulses disrupt pain signals before they reach the brain, providing relief. SCS devices combine advanced neurotechnology with customizable programming, offering a minimally invasive treatment for conditions such as neuropathic pain and failed back surgery syndrome.

The primary types of SCS devices include implantable and non-implantable stimulators. Implantable spinal cord stimulators are surgically placed under the skin and deliver electrical pulses directly to the spinal cord, interfering with pain signals to alleviate chronic discomfort. SCS devices are further categorized into rechargeable and non-rechargeable types. They are used for various applications, including failed back surgery syndrome, complex regional pain syndrome, degenerative disc disease, unsuccessful disk surgery, and other chronic pain conditions. End users include hospitals, ambulatory surgical centers, and neuro clinics.

The spinal cord stimulation devices market research report is one of a series of new reports that provides spinal cord stimulation devices market statistics, including the spinal cord stimulation devices industry's global market size, regional shares, competitors with a spinal cord stimulation devices market share, detailed spinal cord stimulation devices market segments, market trends and opportunities, and any further data you may need to thrive in the spinal cord stimulation devices industry. This spinal cord stimulation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The spinal cord stimulation devices market consists of sales of implantable pulse generators (IPGs), leads and electrodes, MRI-compatible SCS devices, and hybrid stimulation systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.